Bridge Pharmaceuticals intends to work with research groups in Asia with promising drug candidates and supply technical expertise in the skills that will be needed to bring them to market in the US and Europe.
Aside from quality assurance and regulatory advice, Bridge will also offer preclinical capabilities including medicinal chemistry, assay development and screening, toxicology, pharmacokinetics and metabolism, formulation, and protein expression.
"For perhaps the first time, validated FDA drug development expertise is being integrated with flagship bioresearch laboratories in Asia," said Peter Liu, chairman of WI Harper Group, which led a just-completed $3.5 million (€2.9m) fund-raising for the new company. He added that the benefit for the Asian groups would be shorter cycle times at greatly reduced costs.
Meanwhile, in addition to providing drug development services, Bridge plans to develop its own drug pipeline. The company has acquired an option to in-license three late-stage preclinical drugs for treatment of cancer from SRI.